3-Oxa-9-azoniatricyclo-(3.3.1.02,4)nonan, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methylbromid,(7(S)-(1 alpha, 2 beta, 4 beta,5 alpha, 7 beta)-

Bezeichnung:3-Oxa-9-azoniatricyclo-(3.3.1.02,4)nonan, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methylbromid,(7(S)-(1 alpha, 2 beta, 4 beta,5 alpha, 7 beta)-

CAS-Nr149-64-4

Englisch Name:Scopolamine butylbromide

CBNumberCB9126868

SummenformelC21H30BrNO4

Molgewicht440.37

MOL-Datei149-64-4.mol

Synonyma

N-Butylhyosciniumbromid

3-Oxa-9-azoniatricyclo-(3.3.1.02,4)nonan, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methylbromid,(7(S)-(1 alpha, 2 beta, 4 beta,5 alpha, 7 beta)-

3-Oxa-9-azoniatricyclo-(3.3.1.02,4)nonan, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methylbromid,(7(S)-(1 alpha, 2 beta, 4 beta,5 alpha, 7 beta)- physikalisch-chemischer Eigenschaften

Schmelzpunkt	142-1440C
alpha	D20 -20.8° (c = 3 in water)
storage temp.	2-8°C
Löslichkeit	H₂O: 50 mg/mL
Aggregatzustand	powder
Farbe	white
Optische Aktivität	[α]25/D 20.8°, c = 3 in H2O(lit.)
CAS Datenbank	149-64-4(CAS DataBase Reference)

Sicherheit

Kennzeichnung gefährlicher	Xn
R-Sätze:	22
WGK Germany	3
RTECS-Nr.	YM3500000
Toxizität	LD50 in mice (mg/kg): 15.6 i.v.; 74 i.p.; 570 s.c.; 3000 orally (Stockhaus, Wick)

Gefahreninformationscode (GHS)

Scopolamine butylbromide Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R22:Gesundheitsschädlich beim Verschlucken.
Chemische Eigenschaften
Crystalline Solid
Originator
Butylscopolamine,China Pharm
Verwenden
(?)-Scopolamine N-butyl bromide was used as standard in designing a procedure for quantification of compounds using CE-MS.⁸
Verwenden
Anticholinergic. Antispasmodic
Definition
ChEBI: Butylscopolamine bromide is an organic bromide salt of butylscopolamine. It is an antispasmodic drug which can relieve painful stomach cramps (including those linked with irritable bowel syndrome), bladder and menstrual cramps. It has a role as a muscarinic antagonist and an antispasmodic drug. It is an organic bromide salt and a quaternary ammonium salt. It contains a butylscopolamine.
Manufacturing Process
1300 g of scopolamine base and 350 g of n-butylbromide in 600 ml acetonitrile is heated at 65°C for 160 hours. The oil obtained is dissolved in methanol. The solution is cooled and crystalline scopolamine N-n-butylbromide is filtered. After recrystallization from methanol was obtained scopolamine N-n-butylbromide with melting point 142-144°C and [α]d 20 = -20.5° (3% solution in water); yield 65%.
Therapeutic Function
Anticholinergic, Spasmolytic, Antitussive
Biochem/physiol Actions
Competitive muscarinic acetylcholine receptor antagonist; antispasmodic.
Clinical Use
Symptomatic relief of gastrointestinal or genitourinary disorders due to smooth muscle spasm Bowel colic
Excessive respiratory secretions
target
AChR
Stoffwechsel
The main metabolic pathway is the hydrolytic cleavage of the ester bond. Orally administered hyoscine butylbromide is excreted in the faeces and in the urine. Studies in man show that 2-5% of radioactive doses is eliminated renally after oral, and 0.7-1.6% after rectal administration. Approximately 90% of recovered radioactivity can be found in the faeces after oral administration. The urinary excretion of hyoscine butylbromide is less than 0.1% of the dose. The metabolites excreted via the renal route bind poorly to muscarinic receptors and are therefore not considered to contribute to the effect of the hyoscine butylbromide.

Scopolamine butylbromide Upstream-Materialien And Downstream Produkte

3-Oxa-9-azoniatricyclo-(3.3.1.02,4)nonan, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methylbromid,(7(S)-(1 alpha, 2 beta, 4 beta,5 alpha, 7 beta)- Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

149-64-4, Scopolamine butylbromide Verwandte Suche:

Send Inquriy